Multiple factors other than p53 influence colon cancer sensitivity to paclitaxel

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 4, 2000, Pages 329-337

  Sharma, Neeraj ^a   Ramachandran, Satya ^a   Bowers, Mark ^a   Yegappan, Manni ^a   Brown, Ronald ^a   Aziz, Shewan ^a   Chapman, Robert ^a   Yu, Bennett W ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

bax; bcl 2; MDR 1; p53; Paclitaxel

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TAXANE DERIVATIVE;

ARTICLE; CANCER RESISTANCE; CELL CYCLE; COLON CARCINOMA; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0033781815     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000155     Document Type: Article

References (50)

1. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas
2. Colorectal cancer: The challenge
3. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
4. Antisense therapy for lymphomas
5. p53 status does not affect sensitivity of human ovarian cancer ceil lines to paclitaxel
6. p53 activity and chemotherapy
7. p53 functions as a cell cycle control protein in osteo-sarcomas
8. Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells
9. Anti-tumor activity of paclitaxel (Taxol) analogues on MDR-positive human cancer cells
10. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after Taxol or vincristine treatment
11. Abrogation of Taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids
12. Prolonging the exposure of human lung cancer cell lines to paclitaxel improves the cytotoxicity
13. MDR1 gene expression in solid tumors
14. Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53
15. Down-regulation of bcl-2 by p53 in breast cancer cells
16. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents
17. Taxol: Mechanisms of action and resistance
18. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells
19. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits Taxol-induced apoptosis of human breast cancer MCF-7 cells
20. Is P-glycoprotein a sufficient marker for multidrug resistance in vivo? Immunohisto-chemical staining for P-glycoprotein in children and adult leukemia: Correlation with clinical outcome
21. P53, cell cycle control and apoptosis: Implications for cancer
22. Increased incidence of p53 mutations is associated with hepatic metastasis in colo-rectal neoplastic progression
23. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage
24. Wildtype p53 is a cell cycle checkpoint determinant following irradiation
25. p53, the cellular gatekeeper for growth and division
26. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines
27. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines
28. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein
29. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlates with in vitro resistance to Taxol and doxorubicin
30. Metastatic colorectal cancer: Advances in biochemical modulation and new drug development
31. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
32. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
33. The dual role: Of mutant p53 protein in chemosensitivity of human cancers
34. Mutations in the p53 gene occur in diverse human tumour types
35. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
36. Promise and problems of Bcl-2 antisense therapy
37. p53 mutations in colorectal cancer
38. Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to u.v.-irradiation or cisplatin
39. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway
40. High levels of p26BCL-2 oncoprotein retard Taxol-induced apoptosis in human pre-B leukemia cells
41. Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance
42. P-glycoprotein: Clinical significance and methods of analysis
43. A phase II trial of 96-hour infusional paclitaxel with pharmacokinetic analysis in metastatic colorectal cancer
44. Cancer. A deadly inheritance
45. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
46. p53 and chemosensitivity
47. Antisense c-myc oligonucleotides inhibit growth of human colon carcinoma cells
48. Tumor suppressor p53 can participate in transcriptional induction of the GADD45 promoter in the absence of direct DNA binding
49. Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration